权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Studies of Hirano Bodies in Living Cells

活细胞中平野体的研究

基本信息

批准号：
8456162
负责人：
Marcus Fechheimer
金额：
$ 32.06万
依托单位：
UNIVERSITY OF GEORGIA
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-07-01 至 2016-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8456162
关键词：
Actin-Binding Protein Actins Affect Alzheimer&apos s Disease Alzheimer&apos s disease model Amyloid Amyloid beta-Protein Amyloid beta-Protein Precursor Animal Model Attenuated Autophagocytosis Behavioral Binding Proteins Biological Models Brain Breeding Cell Culture Techniques Cell Death Cells Clear Cell Cultured Cells Cytoskeleton Deposition Deterioration Development Disease Disease Progression Electrophysiology (science)Event Family Caregiver Family Study Family member Genes Genetic Goals Health Hippocampus (Brain)Immunohistochemistry Impaired cognition Inherited Injection of therapeutic agent Laboratories Lead Learning Life Link Measures Memory Microtubules Modeling Mus Nerve Degeneration Neurodegenerative Disorders Neurofibrillary Tangles Neurons Outcome Pathology Pathway interactions Patients Pharmaceutical Preparations Phenotype Physiological Platelet-Derived Growth Factor Play Process Protein Fragment Proteins Proteolytic Processing Reporting Role Senile Plaques Structure Symptoms Synapses Synaptic plasticity Testing Toxic effect Transactivation Transgenes Transgenic Mice Transgenic Organisms Work behavior test brain cell cell growth cognitive function drug development gain of function genetic analysis in vivo mouse model neurofibrillary tangle formation neuropathology neurotoxicity normal aging novel progressive neurodegeneration promoter protective effect public health relevance tau Proteins therapy development

项目摘要

DESCRIPTION (provided by applicant): Alzheimer's disease is characterized by profound progressive neurodegeneration that has devastating effects not only on patients but also on families and caregivers. At present, there is no cure for Alzheimer's disease, and current treatments provide modest delay in progression in a subset of all patients. It is essential to identify pathways that can modulate the development of toxicity in order to develop new treatments. Studies of families with genetically inherited neurodegenerative disease, mouse models of Alzheimer's disease, and cell culture models implicate the amyloid beta peptide, the amyloid precursor protein from which amyloid beta is derived, and the microtubule binding protein tau in pathways that lead to loss of cognitive function. Hirano bodies are actin-rich structures that appear in the brain in increased numbers in association with many conditions including Alzheimer's disease. The physiological function of Hirano bodies is not known. However, it is known that Hirano bodies accumulate COOH terminal regions of the amyloid precursor protein and also tau. Therefore, Hirano bodies could influence the progression of Alzheimer's disease. We have recently developed cell culture models and a transgenic mouse model for studies of Hirano bodies. The long term goal of this project is to understand the impact of Hirano bodies on the progression of disease. The goal of this proposal is to test the hypothesis that Hirano bodies either promote or protect from development of pathology in Alzheimer's disease. To achieve this objective, a mouse model of Hirano bodies will be crossed with transgenic Alzheimer's model mice that have symptoms of neurodegeneration induced either by amyloid precursor protein or tau. The outcomes will be assessed using immunohistochemistry, electrophysiology, and behavioral studies to assess the effect of Hirano bodies on development of neuropathology and cognitive decline in vivo. These studies will critically test the hypothesis that Hirano bodies can modulate neurotoxicity in Alzheimer's disease. In addition, the studies will reveal whether Hirano bodies can affect toxicity initiated by pathways involving amyloid precursor protein and/or tau. If the results show that Hirano bodies can modulate the progression of this disease, then pathways involved in formation or degradation of Hirano bodies would be identified as novel targets for drug development to treat Alzheimer's disease.

描述（由申请人提供）：阿尔茨海默病的特征是严重的进行性神经变性，不仅对患者，而且对家庭和护理人员都有破坏性影响。目前，还没有治愈阿尔茨海默病的方法，目前的治疗方法在所有患者的一个子集中提供了适度的进展延迟。为了开发新的治疗方法，必须确定可以调节毒性发展的途径。对遗传性神经退行性疾病家族、阿尔茨海默病小鼠模型和细胞培养模型的研究表明，淀粉样蛋白β肽、淀粉样蛋白β衍生的淀粉样蛋白前体蛋白和微管结合蛋白tau在导致认知功能丧失的途径中。平野体是富含肌动蛋白的结构，其在大脑中出现的数量增加与包括阿尔茨海默病在内的许多疾病有关。平野小体的生理功能尚不清楚。然而，已知Hirano小体积累淀粉样前体蛋白的COOH末端区域以及tau。因此，平野小体可能影响阿尔茨海默病的进展。我们最近开发了细胞培养模型和转基因小鼠模型研究平野小体。该项目的长期目标是了解平野小体对疾病进展的影响。本提案的目的是检验平野小体促进或保护阿尔茨海默病病理发展的假设。为了实现这一目标，将Hirano小体的小鼠模型与具有由淀粉样前体蛋白或tau诱导的神经变性症状的转基因阿尔茨海默病模型小鼠杂交。将使用免疫组织化学、电生理学和行为研究评估结局，以评估Hirano小体对体内神经病理学发展和认知下降的影响。这些研究将严格检验平野小体可以调节阿尔茨海默病神经毒性的假设。此外，这些研究将揭示平野小体是否可以影响由涉及淀粉样前体蛋白和/或tau蛋白的途径引发的毒性。如果结果表明，平野小体可以调节这种疾病的进展，那么参与平野小体形成或降解的途径将被确定为治疗阿尔茨海默病的药物开发的新靶点。